Elutia Inc. Class A Common Stock (ELUT) Stock Price, Quote & AI Analysis

Live ELUT stock price, real-time charts, AI-powered trade signals, technical analysis, earnings insights, and market sentiment for Elutia Inc. Class A Common Stock.

TradeVae provides AI-driven analysis and real-time market intelligence for Elutia Inc. Class A Common Stock (ELUT), including price action, technical indicators, earnings performance, analyst sentiment, and short-term trade setups.

ELUT
Elutia Inc. Class A Common Stock
real-time
$0.00 +0.00 (+0.00%)
Open
1.100000
High
1.150000
Low
1.045000
Volume
128,556
VWAP
-
Market Cap
$44,836,244.25
52W Range
$0.50 - $3.46
P/E Ratio
-
EPS
-
Debt/Equity
-
EV/EBITDA
-
Upcoming Earnings
May 6, 2026 Q1
Market
EPS Estimate: $-0.1224
Revenue Estimate: $3,417,000.00
Loading chart...

AI Analysis

Explore comprehensive AI-powered analysis including summary insights, bull and bear cases, key risks, and factors to watch.

Loading...

Generating AI analysis...

-
-
-
-

Elutia Inc. Class A Common Stock's fundamentals reflect its scale, profitability, and position within the global technology sector. Key valuation and financial metrics are summarized below, followed by detailed financial statements.

Elutia Inc. Class A Common Stock Overview

Company information

Company Overview

Elutia, Inc. is a biotechnology company, which engages in the provision of biologic products to improve compatibility between medical devices and the patients who need them. It operates through the following segments: Device Protection, Women’s Health, and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women’s Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Cardiovascular segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Gaithersburg, MD.

Company Details
Market Cap
$46.12M
Shares Outstanding
42,701,184
Weighted Shares Outstanding
42,701,185
CEO
Charles Randal Mills
Address
12510 PROSPERITY DRIVE, SILVER SPRING, MD, 20904
Employees
51
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
XNAS

Technical Indicators

Key technical analysis metrics and signals

Loading...

Loading technical indicators...

Valuation Metrics

Key valuation ratios and comparisons

Loading...

Loading valuation metrics...

Elutia Inc. Class A Common Stock Earnings & Financial Statements

Earnings Calendar

Upcoming earnings dates and historical surprises

Loading...

Loading earnings calendar...

Financial Statements

Income statements, balance sheets, and cash flow

Loading...

Loading income statements...

Loading...

Loading balance sheets...

Loading...

Loading cash flow statements...